- Home
- STGW vs VRDN Comparison
STGW vs VRDN Comparison
Compare STGW & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STGW
- VRDN
- Stock Information
- Founded
- STGW 1980
- VRDN 2006
- Country
- STGW United States
- VRDN United States
- Employees
- STGW N/A
- VRDN N/A
- Industry
- STGW
- VRDN Medical Specialities
- Sector
- STGW
- VRDN Health Care
- Exchange
- STGW Nasdaq
- VRDN Nasdaq
- Market Cap
- STGW 1.4B
- VRDN 1.5B
- IPO Year
- STGW N/A
- VRDN N/A
- Fundamental
- Price
- STGW $5.57
- VRDN $19.65
- Analyst Decision
- STGW Buy
- VRDN Strong Buy
- Analyst Count
- STGW 5
- VRDN 11
- Target Price
- STGW $8.17
- VRDN $38.80
- AVG Volume (30 Days)
- STGW 884.5K
- VRDN 863.3K
- Earning Date
- STGW 11-06-2025
- VRDN 11-11-2025
- Dividend Yield
- STGW N/A
- VRDN N/A
- EPS Growth
- STGW N/A
- VRDN N/A
- EPS
- STGW N/A
- VRDN N/A
- Revenue
- STGW $2,858,547,000.00
- VRDN $305,000.00
- Revenue This Year
- STGW $4.81
- VRDN N/A
- Revenue Next Year
- STGW $8.73
- VRDN $35,092.81
- P/E Ratio
- STGW N/A
- VRDN N/A
- Revenue Growth
- STGW 9.37
- VRDN 5.90
- 52 Week Low
- STGW $4.03
- VRDN $9.90
- 52 Week High
- STGW $8.18
- VRDN $27.20
- Technical
- Relative Strength Index (RSI)
- STGW 52.82
- VRDN 59.83
- Support Level
- STGW $5.33
- VRDN $18.12
- Resistance Level
- STGW $5.74
- VRDN $20.51
- Average True Range (ATR)
- STGW 0.18
- VRDN 1.00
- MACD
- STGW -0.04
- VRDN 0.06
- Stochastic Oscillator
- STGW 52.17
- VRDN 65.87
About STGW Stagwell Inc.
Stagwell Inc is the challenger holding company built to transform marketing. It delivers scaled creative performance for the world's ambitious brands, connecting culture-moving creativity with a technology to harmonize the art and science of marketing. The company's segments include Integrated Agencies Network; Brand Performance Network; and Communications Network. It generates maximum revenue from the Integrated Agencies Network segment. Geographically, it derives a majority of its revenue from the United States.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).